SSAO Substrates Exhibiting Insulin-Like Effects in Adipocytes as a Promising Treatment Option for Metabolic Disorders

Abstract

Owing to the parallelism between the in vitro insulin mimicry and the in vivo improvement of glucose handling elicited by benzylamine in rodents, the SSAO/VAP-1 substrates, with stronger effects on human adipocytes than benzylamine, show promising applications for the treatment of insulin resistance.